Lymphoma Australia is excited to let you know that eligible patients with Mycosis Fungoides – a type of cutaneous (skin) T-cell lymphoma now have another treatment option. As of November 1st, 2024, LEDAGA® gel is available on Australia’s Pharmaceutical Benefits Scheme (PBS). This is a huge step forward for adults with Mycosis Fungoides. The active ingredient of this topical treatment is Chlormethine Hydrochloride, which is an alkylating agent. This means it’s a type of chemotherapy in a gel form and is applied directly to the affected skin.
Having this treatment listed on the PBS provides a more affordable and convenient option for eligible patients to manage their condition.
To qualify for this treatment, patients must meet certain criteria:
- the disease should be at an early stage (IA, IB, or IIA), confirmed by a biopsy
- affect only a limited body surface area (up to 25%)
- patient must be over the age of 18.
Only dermatologists or hematologists can prescribe it, with approvals allowing for up to four weeks of treatment per prescription.
Healthcare professionals are encouraged to familiarise themselves with LEDAGA’s® prescribing details, including proper use and precautions. More information can be found in the product’s official documentation. This is a promising development for improving care and access for those living with MF-CTCL.
